Want to see HK:7666 full AI Analyst Report?
7666 Stock Chart & Stats
$13.88
-$0.80(-5.45%)
―
--
Day’s Range― - ―
52-Week Range$9.46 - $29.98
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
HK$16.42B
Enterprise Value$15.05K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.48
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,083,110,100
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio3.01
Price to Book (P/B)24.28
Price to Sales (P/S)247.19
P/FCF Ratio-185.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$18.71Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue And Gross Margin RecoveryThe sharp revenue rebound and improved gross margin indicate stronger commercial traction and better unit economics. If sustained, these improvements can provide a more credible path toward covering the company’s still-heavy operating cost base.
Balance Sheet De-riskingThe shift to positive equity and substantial debt reduction materially strengthen financial resilience. Lower leverage should reduce solvency pressure and interest burdens, giving management more flexibility to fund development while pursuing operational improvement.
Narrower Cash BurnA reduction in cash burn is an encouraging operational trend for a development-stage biotechnology company. Continued improvement could extend the funding runway and reduce financing pressure, even though the business remains materially cash-flow negative.
Bears Say
Severe Operating LossesOperating losses remain exceptionally large relative to revenue, showing that the current cost structure is not close to breakeven. This weakens earnings quality and means future revenue growth must be substantial before the business can generate durable operating profits.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the company is not self-funding its activities. Continued development spending and cash deficits may require additional financing, creating dilution or liquidity risk if profitability does not improve.
Weak Shareholder ReturnsPositive equity has not yet translated into attractive returns for shareholders because substantial losses continue to erode earnings power. Persistently negative returns indicate that capital is not currently being converted into sustainable value creation.
Metis TechBio Co., Ltd. Class H News
7666 FAQ
What was Metis TechBio Co., Ltd. Class H’s price range in the past 12 months?
Metis TechBio Co., Ltd. Class H lowest stock price was $9.46 and its highest was $29.98 in the past 12 months.
What is Metis TechBio Co., Ltd. Class H’s market cap?
Metis TechBio Co., Ltd. Class H’s market cap is HK$16.42B.
When is Metis TechBio Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Metis TechBio Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Metis TechBio Co., Ltd. Class H overvalued?
According to Wall Street analysts Metis TechBio Co., Ltd. Class H’s price is currently Undervalued.
Does Metis TechBio Co., Ltd. Class H pay dividends?
Metis TechBio Co., Ltd. Class H does not currently pay dividends.
What is Metis TechBio Co., Ltd. Class H’s EPS estimate?
Metis TechBio Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Metis TechBio Co., Ltd. Class H have?
Metis TechBio Co., Ltd. Class H has 1,083,110,100 shares outstanding.
What happened to Metis TechBio Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Metis TechBio Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:7666
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Metis TechBio Co., Ltd. Class H Stock Smart Score
Learn more about TipRanks Smart Score
Company Description
Metis TechBio Co., Ltd. Class H
Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission is to facilitate the delivery and application of active agents within carbon-based life forms, operating in both the Chinese Mainland and the United States. Central to its offerings is NanoForge, a comprehensive suite of interconnected technologies that includes a novel lipid library, foundational artificial intelligence models, METiSAIAgent, cutting-edge quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. Furthermore, Metis TechBio has developed specialized platforms like AiTEM, AiLNP, and AiRNA. These tools are crucial for simulating, predicting, and interpreting interactions at the nanoscale, thereby enabling the precise design, optimization, and validation of sophisticated nanomaterials and their associated payloads. The company provides its services through a three-tiered system: a foundational dry-wet data layer supported by integrated laboratory infrastructure, a model layer featuring METiS AI foundational models, and an application layer known as METiSAgentv. Metis TechBio primarily serves a diverse clientele, including pharmaceutical companies, biotechnology firms, and medical research institutions.
7666 Stock 12 Month Forecast
Average Price Target
$18.71
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
Mabwell (Shanghai) Bioscience Co., Ltd. Class H
―